Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • METTL14-m6A Pathway Modulates Inflammation in Ulcerative Col

    2026-05-11

    Deciphering METTL14-m6A Regulation of Inflammation in Ulcerative Colitis

    Study Background and Research Question

    Ulcerative colitis (UC), a major subtype of inflammatory bowel disease (IBD), is characterized by chronic, relapsing inflammation of the colon. While its etiology is multifactorial—encompassing genetic, immunological, microbial, and environmental components—the precise mechanisms underlying persistent mucosal inflammation remain unclear (reference paper). Recent attention has focused on epigenetic regulation, especially N6-methyladenosine (m6A) RNA modifications, as pivotal modulators of RNA stability and inflammatory responses. The methyltransferase complex subunit METTL14, a key m6A 'writer,' is known to regulate these modifications, but its specific role in UC pathogenesis, particularly regarding long non-coding RNAs (lncRNAs), had not been comprehensively explored prior to this study.

    Key Innovation from the Reference Study

    This research elucidates a novel mechanistic pathway in which METTL14-catalyzed m6A modification of the lncRNA DHRS4-AS1 modulates downstream inflammation in UC. Specifically, it demonstrates that loss of METTL14 reduces m6A on DHRS4-AS1, diminishing its expression and thereby dysregulating the miR-206/adenosine A3 receptor (A3AR) axis. The study provides direct evidence that this pathway governs NF-κB-mediated cytokine production and apoptotic responses in intestinal epithelial cells, positioning the METTL14–DHRS4-AS1–miR-206/A3AR axis as a central regulatory node in UC inflammatory injury (reference paper).

    Methods and Experimental Design Insights

    The authors used a combination of in vitro and in vivo models to dissect the METTL14-m6A-regulated network. Human colonic epithelial Caco-2 cells were subjected to METTL14 knockdown and treated with TNF-α to model inflammatory conditions. Assays for cell viability, apoptosis (cleaved PARP, cleaved caspase-3, Bcl-2 levels), and NF-κB pathway activation were performed. In parallel, a dextran sulfate sodium (DSS)-induced murine colitis model was employed to evaluate colonic injury and inflammation after METTL14 suppression. High-throughput approaches such as RNA immunoprecipitation (RIP) and methylated RNA immunoprecipitation (MeRIP) clarified m6A modification status on DHRS4-AS1, while gain- and loss-of-function experiments for DHRS4-AS1 and miR-206/A3AR were conducted to confirm mechanistic links.

    Protocol Parameters

    • assay | METTL14 siRNA knockdown | Caco-2 cells, 40 nM siRNA | To assess impact on m6A modification and inflammation | reference_paper
    • assay | TNF-α stimulation | 20 ng/mL, 24 h | Mimics proinflammatory stress in vitro | reference_paper
    • assay | DHRS4-AS1 overexpression | Plasmid-mediated, 2 μg/well | Rescue of METTL14 knockdown phenotype | reference_paper
    • assay | DSS-induced colitis | 2.5% DSS in drinking water, 7 days | Models UC in mice | reference_paper
    • assay | Cleaved PARP/caspase-3 detection | Western blot, 1:1000 antibody dilution | Quantifies apoptosis | reference_paper
    • assay | m6A MeRIP-qPCR | 5 μg RNA/IP reaction | Maps m6A on DHRS4-AS1 | reference_paper
    • assay | Use of S-adenosylhomocysteine hydrolase inhibitors (e.g., 3-Deazaadenosine) | 10–50 μM, variable incubation | For mechanistic methylation suppression studies | workflow_recommendation

    Core Findings and Why They Matter

    1. METTL14 Loss Promotes Inflammatory Injury: METTL14 knockdown in Caco-2 cells decreased viability and increased apoptosis, as evidenced by elevated cleaved PARP and caspase-3, and reduced Bcl-2. NF-κB activation and proinflammatory cytokine secretion (IL-1β, IL-6, TNF-α, IFN-γ) were markedly upregulated (reference paper).

    2. METTL14-m6A Control of DHRS4-AS1: Reduced METTL14 led to diminished m6A modification and lower expression of DHRS4-AS1. Restoration of DHRS4-AS1 counteracted the proinflammatory and proapoptotic effects of METTL14 deficiency, supporting a causative functional link.

    3. DHRS4-AS1–miR-206/A3AR Axis: DHRS4-AS1 acts as a competing endogenous RNA (ceRNA), sequestering miR-206. Loss of DHRS4-AS1 releases miR-206, which directly targets A3AR mRNA, reducing its expression. Since A3AR modulates anti-inflammatory signaling, this axis provides a mechanistic bridge from m6A epigenetic regulation to cytokine output and cell death (reference paper).

    4. In Vivo Confirmation: In DSS-induced murine colitis, METTL14 silencing exacerbated colonic damage, increased disease activity index (DAI), and upregulated inflammatory mediators, confirming translational relevance.

    Comparison with Existing Internal Articles

    Several internal resources contextualize the relevance of methylation inhibition in inflammation and infection research:

    These internal guides reinforce the mechanistic and workflow-level importance of methylation inhibition for both fundamental and translational studies in inflammation and viral infection research.

    Limitations and Transferability

    While the study robustly links METTL14-mediated m6A modification to lncRNA- and miRNA-driven regulation of inflammation, some limitations warrant consideration. The complex interplay among multiple m6A regulators, diverse lncRNAs, and cell-type specificity in the gut microenvironment may influence generalizability. The in vivo DSS model, though widely used, does not recapitulate all aspects of human UC. Additionally, the long-term consequences of modulating this pathway, particularly via pharmacological inhibition or genetic editing, require further investigation (reference paper).

    Why this cross-domain matters, maturity, and limitations

    The mechanistic insights from this study, focusing on epigenetic regulation of inflammation, have implications for both inflammatory and infectious disease research. Internal articles highlight that S-adenosylhomocysteine hydrolase inhibitors like 3-Deazaadenosine are already established tools in preclinical antiviral modeling (notably against Ebola virus) and methylation inhibition assays (internal article). However, translation of findings from inflammatory models to antiviral settings should be approached with care. While methylation machinery is a shared regulatory axis, disease context, cell type, and compensatory pathways may yield divergent outcomes.

    Research Support Resources

    To experimentally probe methylation-dependent pathways, including those involving m6A or METTL14, researchers can utilize validated S-adenosylhomocysteine hydrolase inhibitors such as 3-Deazaadenosine (SKU B6121). This compound, available from APExBIO, enables controlled suppression of SAM-dependent methyltransferase activity to interrogate epigenetic regulation in both inflammation and preclinical antiviral workflows (source: internal article). For further methodological guidance and troubleshooting, consult scenario-driven guides or data-backed protocols as cited above.